LifeVantage (LFVN) Proxy filing summary

Executive summary

• Fiscal year 2026 was a period of transition, with leadership succession, strategic investments, and enhanced governance practices.

• Priorities for fiscal year 2027 include strengthening fundamentals, accelerating growth, modernizing technology, and expanding customer engagement.

• The company is leveraging a scientific platform, experienced leadership, and an engaged board to pursue long-term value creation.

Voting matters and shareholder proposals

• Stockholders will vote to elect six directors, approve a non-binding say-on-pay resolution, and ratify Deloitte as the independent auditor for FY2027.

• The board unanimously recommends voting FOR all director nominees and proposals.

• Shareholder proposals for the 2028 annual meeting must be submitted by May 21, 2027, for inclusion in the proxy statement.

Board of directors and corporate governance

• The board consists of six nominees with diverse backgrounds in technology, finance, consumer products, and international operations.

• Board leadership is separated between the chair (independent) and CEO roles, supporting effective risk oversight.

• Committees include audit, nominating and governance, and compensation, all composed of independent directors.

• The board emphasizes diversity, transparency, and regular engagement with shareholders.

• A cooperation agreement with major shareholders influenced board composition and director nominations.